Free Trial
NASDAQ:KOD

Kodiak Sciences Q2 2025 Earnings Report

Kodiak Sciences logo
$4.74 -0.07 (-1.46%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$4.64 -0.11 (-2.22%)
As of 08:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kodiak Sciences EPS Results

Actual EPS
N/A
Consensus EPS
-$1.01
Beat/Miss
N/A
One Year Ago EPS
N/A

Kodiak Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kodiak Sciences Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Kodiak Sciences Earnings Headlines

Penny Stocks To Watch In July 2025
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Kodiak Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email.

About Kodiak Sciences

Kodiak Sciences (NASDAQ:KOD), Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for retinal diseases. Headquartered in Palo Alto, California, Kodiak leverages proprietary antibody biopolymer conjugate (ABC) technology to create targeted treatments that aim to improve durability, durability and efficacy in the eye. The company was founded in 2009 and has steadily advanced a pipeline of product candidates designed to address unmet needs in chronic ophthalmic conditions.

The company’s lead candidate, KSI-301, is an anti-VEGF antibody biopolymer conjugate that is being evaluated in pivotal Phase 3 studies for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). By combining a high-molecular-weight polymer with an anti-VEGF antibody, KSI-301 is engineered to extend treatment intervals and potentially reduce the frequency of intravitreal injections for patients. Kodiak has also initiated early-stage programs exploring novel targets in retinal vascular disease and inherited retinal disorders.

Kodiak Sciences operates research and development facilities in both the United States and Europe, enabling global collaboration and clinical trial execution across multiple geographies. The company has established strategic partnerships with academic institutions and contract research organizations to support its translational efforts. Kodiak’s international reach is further strengthened by regulatory interactions in key markets, positioning the company to seek approvals and commercial launches in North America, Europe and select Asia-Pacific territories.

Leadership at Kodiak Sciences includes President and Chief Executive Officer Victor Perlroth, who brings extensive experience in ophthalmology drug development, and Chief Medical Officer Manjula Mahajan, M.D., a recognized expert in retinal disease clinical research. The management team and board combine scientific, clinical and commercial expertise to drive the advancement of Kodiak’s pipeline. As Kodiak continues its late-stage programs, the company remains committed to delivering transformative therapies for patients suffering from vision-threatening conditions.

View Kodiak Sciences Profile

More Earnings Resources from MarketBeat